×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
GNPX – genprex, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
GNPX
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/16
09:27 am
gnpx
Genprex Receives Safety Review Committee Approval to Advance to Phase 2 Portion of Acclaim-3 Clinical Trial of Reqorsa® Gene Therapy in Combination with Tecentriq® in Extensive Stage Small Cell Lung Cancer [Yahoo! Finance]
Low
Report
Genprex Receives Safety Review Committee Approval to Advance to Phase 2 Portion of Acclaim-3 Clinical Trial of Reqorsa® Gene Therapy in Combination with Tecentriq® in Extensive Stage Small Cell Lung Cancer [Yahoo! Finance]
12/16
09:15 am
gnpx
Genprex Receives Safety Review Committee Approval to Advance to Phase 2 Portion of Acclaim-3 Clinical Trial of Reqorsa® Gene Therapy in Combination with Tecentriq® in Extensive Stage Small Cell Lung Cancer
Medium
Report
Genprex Receives Safety Review Committee Approval to Advance to Phase 2 Portion of Acclaim-3 Clinical Trial of Reqorsa® Gene Therapy in Combination with Tecentriq® in Extensive Stage Small Cell Lung Cancer
11/20
09:30 am
gnpx
Genprex Signs Exclusive License to Additional Gene Therapy Technologies with the University of Michigan for the Treatment of Lung Cancer [Yahoo! Finance]
High
Report
Genprex Signs Exclusive License to Additional Gene Therapy Technologies with the University of Michigan for the Treatment of Lung Cancer [Yahoo! Finance]
11/20
09:29 am
gnpx
Genprex Signs Exclusive License to Additional Gene Therapy Technologies with the University of Michigan for the Treatment of Lung Cancer
High
Report
Genprex Signs Exclusive License to Additional Gene Therapy Technologies with the University of Michigan for the Treatment of Lung Cancer
11/5
09:29 am
gnpx
Genprex Collaborators Present Positive Preclinical Data on Reqorsa® Gene Therapy at the Society for Immunotherapy of Cancer 2024 Annual Meeting
Medium
Report
Genprex Collaborators Present Positive Preclinical Data on Reqorsa® Gene Therapy at the Society for Immunotherapy of Cancer 2024 Annual Meeting
10/31
09:31 am
gnpx
Genprex to Participate in 2024 BIO Europe Conference [Yahoo! Finance]
Low
Report
Genprex to Participate in 2024 BIO Europe Conference [Yahoo! Finance]
10/31
09:29 am
gnpx
Genprex to Participate in 2024 BIO Europe Conference
Medium
Report
Genprex to Participate in 2024 BIO Europe Conference
10/28
09:39 am
gnpx
Genprex Collaborators Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer, Mesothelioma and Glioblastoma [Yahoo! Finance]
High
Report
Genprex Collaborators Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer, Mesothelioma and Glioblastoma [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
12/16
09:15 am
gnpx
Form 8-K Genprex, Inc. For: Dec 16
High
Report
Form 8-K Genprex, Inc. For: Dec 16
12/6
05:55 pm
gnpx
Form 4 Genprex, Inc. For: Dec 05 Filed by: Moreno Toscano Jose Antonio
Neutral
Report
Form 4 Genprex, Inc. For: Dec 05 Filed by: Moreno Toscano Jose Antonio
12/6
05:54 pm
gnpx
Form 4 Genprex, Inc. For: Dec 05 Filed by: Wilson William R Jr.
Low
Report
Form 4 Genprex, Inc. For: Dec 05 Filed by: Wilson William R Jr.
12/6
05:52 pm
gnpx
Form 4 Genprex, Inc. For: Dec 05 Filed by: LONGNECKER BRENT M
Low
Report
Form 4 Genprex, Inc. For: Dec 05 Filed by: LONGNECKER BRENT M
12/6
05:50 pm
gnpx
Form 4 Genprex, Inc. For: Dec 05 Filed by: Confer Ryan M.
Low
Report
Form 4 Genprex, Inc. For: Dec 05 Filed by: Confer Ryan M.
12/6
05:48 pm
gnpx
Form 4 Genprex, Inc. For: Dec 05 Filed by: Berger Mark Stanley
Low
Report
Form 4 Genprex, Inc. For: Dec 05 Filed by: Berger Mark Stanley
11/20
09:29 am
gnpx
Form 8-K Genprex, Inc. For: Nov 20
High
Report
Form 8-K Genprex, Inc. For: Nov 20
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
1/17
Form 424B5 Genprex, Inc.
228.6%
3/16 Form 3 Genprex, Inc. For: Mar 12 Filed by: Redman Michael Thomas 105.6%
11/19 Genprex Reports Positive Preclinical Data for the Treatment of Some of the Most Resistant Metastatic Lung Cancers 63.2%
1/23 Genprex, Inc. Prices $8,000,000 Common Stock Offering Priced At-The-Market 32.1%
2/11 Genprex and University of Pittsburgh Sign Exclusive License Agreement for Potentially Curative Gene Therapy Candidate for Diabetes 26.8%
1/29 Independent Researchers Find Genprex’s TUSC2 May Be a Novel Target and Biomarker for Thyroid Cancer Therapy 24.4%
2/20 Form 8-K Genprex, Inc. For: Feb 19 22.0%
1/31 Form SC 13G Genprex, Inc. Filed by: INTRACOASTAL CAPITAL, LLC 18.3%
4/21 Form 8-K Genprex, Inc. For: Apr 15 18.2%
2/21 Genprex, Inc. Announces Closing of $17,500,000 Common Stock Offering At-The-Market and Without Warrants 14.2%
3/16 Form 3 Genprex, Inc. For: Mar 12 Filed by: Redman Michael Thomas 105.6%
11/19 Genprex Reports Positive Preclinical Data for the Treatment of Some of the Most Resistant Metastatic Lung Cancers 63.2%
1/23 Genprex, Inc. Prices $8,000,000 Common Stock Offering Priced At-The-Market 32.1%
2/11 Genprex and University of Pittsburgh Sign Exclusive License Agreement for Potentially Curative Gene Therapy Candidate for Diabetes 26.8%
1/29 Independent Researchers Find Genprex’s TUSC2 May Be a Novel Target and Biomarker for Thyroid Cancer Therapy 24.4%
2/20 Form 8-K Genprex, Inc. For: Feb 19 22.0%
1/31 Form SC 13G Genprex, Inc. Filed by: INTRACOASTAL CAPITAL, LLC 18.3%
4/21 Form 8-K Genprex, Inc. For: Apr 15 18.2%
2/21 Genprex, Inc. Announces Closing of $17,500,000 Common Stock Offering At-The-Market and Without Warrants 14.2%
TOP News Decliners
11/20
Genprex Announces $1.26 Million Registered Direct Offering
-35.5%
1/23 Genprex Inc (NASDAQ: GNPX) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. -34.3%
2/19 Form S-3MEF Genprex, Inc. -33.3%
11/22 Form 8-K Genprex, Inc. For: Nov 20 -15.3%
3/31 Form 3/A Genprex, Inc. For: Mar 18 Filed by: Wilson William R Jr. -9.8%
3/20 Form 3 Genprex, Inc. For: Mar 18 Filed by: Wilson William R Jr. -9.2%
1/21 Form 8-K Genprex, Inc. For: Jan 21 -8.7%
12/10 Form PRE 14A Genprex, Inc. For: Jan 27 -8.4%
10/4 Form S-3/A Genprex, Inc. -8.0%
3/3 Genprex to Present at the 2020 LD Micro Virtual Conference -7.5%
1/23 Genprex Inc (NASDAQ: GNPX) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. -34.3%
2/19 Form S-3MEF Genprex, Inc. -33.3%
11/22 Form 8-K Genprex, Inc. For: Nov 20 -15.3%
3/31 Form 3/A Genprex, Inc. For: Mar 18 Filed by: Wilson William R Jr. -9.8%
3/20 Form 3 Genprex, Inc. For: Mar 18 Filed by: Wilson William R Jr. -9.2%
1/21 Form 8-K Genprex, Inc. For: Jan 21 -8.7%
12/10 Form PRE 14A Genprex, Inc. For: Jan 27 -8.4%
10/4 Form S-3/A Genprex, Inc. -8.0%
3/3 Genprex to Present at the 2020 LD Micro Virtual Conference -7.5%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: